EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Perspectives in Amyotrophic Lateral Sclerosis: Biomarkers, Omics, and Gene Therapy Informing Disease and Treatment

Nina Bono iD, Flaminia Fruzzetti iD, Giorgia Farinazzo iD, Gabriele Candiani iD, Stefania Marcuzzo iD

International Journal of Molecular Sciences · 13.06.2025 · 26 (12) · 5671

DOI: 10.3390/ijms26125671 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.06.2025. Verfasst von Nina Bono und 4 weiteren Autor:innen. Beteiligte Einrichtung: genT_LΛB, Department of Chemistry, Materials and Chemical Engineering "Giulio Natta", Politecnico di Milano, 20131 Milan, Italy. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Genetic Therapy, Biomarkers. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health (RRC), CALabria HUB per Ricerca Innovativa ed Avanzata- CALHUB.RIA "Creazione di Hub delle Sci-enze della Vita", AriSLA foundation, "Bulb-Omics".

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of upper and lower motor neurons, leading to muscle weakness, paralysis, and ultimately respiratory failure. Despite advances in understanding its genetic basis, particularly mutations in Chromosome 9 Open Reading Frame 72 (C9orf72), superoxide dismutase 1 (SOD1), TAR DNA-binding protein (TARDBP), and Fused in Sarcoma (FUS) gene, current diagnostic methods result in delayed intervention, and available treatments offer only modest benefits. This review examines innovative approaches transforming ALS research and clinical management. We explore emerging biomarkers, including the fluid-based markers such as neurofilament light chain, exosomes, and microRNAs in biological fluids, alongside the non-fluid-based biomarkers, including neuroimaging and electrophysiological markers, for early diagnosis and patient stratification. The integration of multi-omics data reveals complex molecular mechanisms underlying ALS heterogeneity, potentially identifying novel therapeutic targets. We highlight current gene therapy strategies, including antisense oligonucleotides (ASOs), RNA interference (RNAi), and CRISPR/Cas9 gene editing systems, alongside advanced delivery methods for crossing the blood–brain barrier. By bridging molecular neuroscience with bioengineering, these technologies promise to revolutionize ALS diagnosis and treatment, advancing toward truly disease-modifying interventions for this previously intractable condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisGenetic TherapyBiomarkersHumansC9orf72 ProteinAnimalsGene EditingSuperoxide Dismutase-1

Stichwörter der Autor:innen

advanced diagnosisamyotrophic lateral sclerosisbioengineeringnanotechnologysystems biology approachtherapeutic strategies

Substanzen

BiomarkersC9orf72 ProteinSuperoxide Dismutase-1

Autor:innen und Institutionen

  • genT_LΛB, Department of Chemistry, Materials and Chemical Engineering "Giulio Natta", Politecnico di Milano, 20131 Milan, Italy.
  • Neurology 4-Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
  • Brain-Targeted Nanotechnologies (BraiNs) Lab, Fondazione IRCCS Istituto Neurologico Carlo Besta-Politecnico di Milano, 20133 Milan, Italy.

ORCID-Profile: Nina Bono, Flaminia Fruzzetti, Giorgia Farinazzo, Gabriele Candiani, Stefania Marcuzzo

Förderung

  • Italian Ministry of Health (RRC)
  • CALabria HUB per Ricerca Innovativa ed Avanzata- CALHUB.RIA "Creazione di Hub delle Sci-enze della Vita"
  • AriSLA foundation, "Bulb-Omics"
  • the European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS
  • CALabria HUB per Ricerca Innovativa ed Avanzata—CALHUB.RIA, “Creazione di Hub delle Scienze della Vita” T4-AN-09 prog. ZRPOS2
  • AriSLA foundation, “Bulb-Omics” prog. ZRA124
  • European Union—Next Generation EU—NRRP M6C2—Investment 2.1 Enhancement and strengthening of biomedical research in the NHS

Zitieren

APA

Bono, N., Fruzzetti, F., Farinazzo, G., Candiani, G., & Marcuzzo, S. (2025). Perspectives in Amyotrophic Lateral Sclerosis: Biomarkers, Omics, and Gene Therapy Informing Disease and Treatment. International Journal of Molecular Sciences, 26(12), 5671. https://doi.org/10.3390/ijms26125671

Vancouver

Bono N, Fruzzetti F, Farinazzo G, Candiani G, Marcuzzo S. Perspectives in Amyotrophic Lateral Sclerosis: Biomarkers, Omics, and Gene Therapy Informing Disease and Treatment. International Journal of Molecular Sciences. 2025;26(12):5671. doi:10.3390/ijms26125671

BibTeX
@article{Bono2025,
  author = {Bono, Nina and Fruzzetti, Flaminia and Farinazzo, Giorgia and Candiani, Gabriele and Marcuzzo, Stefania},
  title = {Perspectives in Amyotrophic Lateral Sclerosis: Biomarkers, Omics, and Gene Therapy Informing Disease and Treatment},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {12},
  pages = {5671},
  doi = {10.3390/ijms26125671}
}
Kostenlos starten →